ESMO 2016 | NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer patients

Nicoletta Colombo

Nicoletta Colombo, MD, PhD from the European Institute of Oncology (IEO), Milan, Italy gives an overview of the Phase III ENGOT-OV16/NOVA trial of niraparib versus placebo in platinum-sensitive ovarian cancer patients (NCT01847274). Patients received either placebo or the PARP inhibitor, niraparib. Further, the trial looked at two different patient populations; one with a germline BRCA mutation (gBRCA cohort) and one without a germline BRCA mutation (non-gBRCA cohort). The trial showed a significant progression-free survival (PFS) advantage for patients in the gBRCA cohort (21 vs 5.5 months). Furthermore, there was a significant advantage in terms of PFS in the non-gBRCA cohort (9.3 vs 3.9 months). This shows that the PARP inhibitor niraparib can be used effectively for both groups of patients. Patients in the non-gBRCA cohort were also tested for homologous recombination deficiency (HRD) to determine within the sub-population, which individuals would have the best response to niraparib.
Recorded at the European Society of Medical Oncology (ESMO) 2016 Congress, held in Copenhagen, Denmark.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter